rIFN-γ-mediated growth suppression of platinum-sensitive and -resistant ovarian tumor cell lines not dependent upon arginase inhibition

Journal of Translational Medicine

Volumn 1, Issue , 2003, Pages

  Melichar, Bohuslav ^a   Hu, Wei ^b   Patenia, Rebecca ^b   Melicharová, Karolina ^a   Gallardo, Stacie T ^b   Freedman, Ralph ^b,c  

^a CHARLES UNIVERSITY   (Czech Republic)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

Arginase; Interferon gamma; Ovarian neoplasms

Indexed keywords

ARGINASE; ARGINASE I; ARGINASE II; ARGININE; CISPLATIN; CYTOKINE; INDOLEAMINE 2,3 DIOXYGENASE; INDUCIBLE NITRIC OXIDE SYNTHASE; ISOENZYME; PLATINUM DERIVATIVE; POLYAMINE; RECOMBINANT GAMMA INTERFERON; THYMIDINE; TRITIUM; UNCLASSIFIED DRUG;

AMINO ACID METABOLISM; ANIMAL CELL; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG SENSITIVITY; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; EPITHELIUM TUMOR; FEMALE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OVARY CANCER; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

EID: 4344663790     PISSN: 14795876     EISSN: None     Source Type: Journal    
DOI: 10.1186/1479-5876-1-5     Document Type: Article

References (51)

1. Moncada S, Palmer RMJ, Higgs EA: Nitric oxide: Physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991, 43:109-142.
2. Thomas T, Thomas TJ: Polyamines in cell growth and cell death: molecular mechanisms and therapeutic applications. Cell Mol Life Sci 2001, 58:244-258.
3. Daghigh F, Fukuto JM, Ash DE: Inhibition of rat liver arginase by an intermediate in NO biosynthesis, NG-hydroxy-L-arginine: Implications for the regulation of nitric oxide biosynthesis by arginase. Biochem Bioph Res Com 1994, 202:174-180.
4. Boucher JL, Custot J, Vadon S, Delaforge M, Lepoivre M, Tenu JP, Yapo A, Mansuy D: Nω-hydroxy-L-arginine, an intermediate in the L-arginine to nitric oxide pathway, is a strong inhibitor of liver and macrophage arginase. Biochem Bioph Res Com 1994, 203:1614-1621.
5. Xie K, Huang S, Dong Z, Juang SH, Gutman M, Zie QW, Nathan C, Fidler IJ: Transfection with the inducible nitric oxide synthase gene suppresses tumorigenicity and abrogates metastasis by K-1735 melanoma cells. J Exp Med 1995, 181:1333-1343.
6. Dong Z, Staroselsky AH, Qi Y, Xie K, Fidler IJ: Inverse correlation between expression of inducible nitric oxide synthase activity and production of metastasis in K-1735 murine melanoma cells. Cancer Res 1994, 54:789-793.
7. Jenkins DC, Charles IG, Thomsen LL, Moss DW, Holmes LS, Baylis SA, Rhodes P, Westmore K, Emson PC, Moncada S: Roles of nitric oxide in tumor growth. Proc Natl Acad Sci USA 1995, 92:4392-4396.
8. Kip1, and p53 in IEC-6 cell. Am J Physiol 1999, 276:C684-C691.
9. Stuehr DJ, Nathan CF: Nitric oxide. A macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells. J Exp Med 1989, 169:1543-1555.
10. Modolell M, Corraliza IM, Link F, Soler G, Eichman K: Reciprocal regulation of the nitric oxide synthase/arginase balance in mose bone marrow-derived macrophages by TH1 and TH2 cytokines. Eur J Immunol 1995, 25:1101-1104.
11. Munder M, Eichmann K, Modolell M: Alternative metabolic states in murine macrophages reflected by the nitric oxide synthase/arginase balance: Competitive regulation by CD4+ T cells correlates with Th1/Th2 phenotype. J Immunol 1998, 160:5347-5354.
12. Billiau A: Interferon-γ: Biology and role in pathogenesis. Adv Immunol 1996, 62:61-130.
13. Burke F, Knowles RG, East N, Balkwill FR: The role of indoleamine 2,3-dioxygenase in the anti-tumour activity of human interferon-γ in vivo. Int J Cancer 1995, 60:115-122.
14. Malik STA, Knowles RG, East N, Lando D, Stamp G, Balkwill FR: Antitumor activity of γ-interferon in ascitic and solid tumor models of human ovarian cancer. Cancer Res 1991, 51:6643-6649.
15. Burke F, Smith PD, Crompton MR, Upton C, Balkwill FR: Cytotoxic response of ovarian cancer cell lines to IFN-γ is associated with sustained induction of IRF-1 and p21 mRNA. Brit J Cancer 1999, 80:1236-1244.
16. de la Maza LM, Peterson EM: Dependence of the in vitro antiproliferative activity of recombinant human γ-interferon on the concentration of tryptophan in culture media. Cancer Res 1988, 48:346-350.
17. Ozaki Y, Edelstein MP, Duch DS: Induction of indoleamin 2,3-dioxygenase: A mechanism of the antitumor activity of interferon-g. Proc Natl Acad Sci USA 1988, 85:1242-1246.
18. Pujade-Lauraine E, Guastalla JP, Colombo N, Devillier P, Francois E, Lumoleau P, Monnier A, Nooy M, Mignot L, Bugat R, Marques C, Mousseau M, Netter G, Maloisel F, Larbaoui S, Brandely M: Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy. J Clin Oncol 1996, 14:343-350.
19. Windbichler GH, Hausmaninger H, Stummvoll W, Graf AH, Kainz C, Lohodny J, Denison U, Muller-Holzner E, Marth C: Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial. Brit J Cancer 2000, 82:1138-1144.
20. Freedman RS, Bowen JM, Leibovitz A, Pathak S, Siciliano MJ, Gallager HS, Giovanella BC: Characterization of an ovarian carcinoma cell line. Cancer 1978, 42:2352-2359.
21. Auzenne E, Donato NJ, Li C, Leroux E, Price RE, Farquhar D, Klostergaard J: Superior therapeutic profile of poly-L-glutamic acid-paclitaxel copolymer compared with taxol in xenogeneic compartmental models of human ovarian carcinoma. Clin Cancer Res 2002, 8:573-581.
22. Buick RN, Pullano R, Trent JM: Comparative properties of five human ovarian adenocarcinoma cell lines. Cancer Res 1985, 45:3668-3676.
23. Andrews PA, Albright KD: Mitochondrial defects in cis-diamminedichloridplatinum(II)-resistant human ovarian carcinoma cells. Cancer Res 1992, 52:1895-1901.
24. Corraliza IM, Campo ML, Soler G, Modollel M: Determination of arginase activity in macrophages: a micromethod. J Immunol Methods 1994, 174:231-235.
25. Nash MA, Deavers MT, Freedman RS: The expression of decorin in human ovarian tumors. Clin Cancer Res 2002, 8:1754-1760.
26. Melichar B, Nash MA, Lenzi R, Platsoucas CD, Freedman RS: Expression of costimulatory molecules CD80 and CD86 and their receptors CD28, CTLA-4 on malignant ascites CD3+ tumor infiltrating lymphocytes (TIL) from patients with ovarian and other types of peritoneal carcinomatosis. Clin Exp Immunol 2000, 119:19-27.
27. Koide Y, Yoshida A: The signal transduction mechanism responsible for gamma interferon-induced indoleamine 2,3-dioxygenase gene expression. Infect Immun 1994, 62:948-955.
28. Singh R, Pervin S, Karimi A, Cederbaum S, Chaudhuri G: Arginase activity in human breast cancer cell lines: N-hydroxy-L-arginine selectively inhibits cell proliferation and induces apoptosis in MDA-MB-468 cells. Cancer Res 2000, 60:3305-3312.
29. Melichar B, Ferrandina G, Verschraegen CF, Loercher A, Abbruzzese JL, Freedman RS: Growth inhibitory effects of aromatic fatty acids on ovarian tumor cell lines. Clin Cancer Res 1998, 4:3069-3076.
30. Thomsen LL, Lawton FG, Knowles RG, Beesley JE, Riveros-Moreno V, Moncada S: Nitric oxide synthase activity in human gynecological cancer. Cancer Res 1994, 54:1352-1354.
31. Konur A, Krause SW, Rehli M, Kreutz M, Andreesen R: Human monocytes induce a carcinoma cell line to secrete high amounts of nitric oxide. J Immunol 1996, 157:2109-2115.
32. Jenkins DC, Charles IG, Baylis SA, Lelchuk R, Radomski MW, Moncada S: Human colon cancer cell lines show a diverse pattern of nitric oxide synthase gene expression and nitric oxide generation. Brit J Cancer 1994, 70:847-849.
33. Rieder J, Jahnke R, Schloesser M, Seibel M, Czechowski M, Marth C, Hoffmann G: Nitric oxide-dependent apoptosis in ovarian carcinoma cell lines. Gyn Oncol 2001, 82:172-176.
34. Garban HJ, Bonavida B: Nitric oxide sensitizes ovarian tumor cells to fas-induced apoptosis. Gyn Oncol 1999, 73:257-264.
35. Rieder J, Marth C, Totzke G, Smolny M, Seibel M, Hoffmann G: Different patterns of inducible nitric oxide synthase gen expression in ovarian carcinoma cell lines. Anticancer Res 2000, 20:3251-3258.
36. Buga GM, Wei LH, Bauer PM, Fukuto JM, Ignarro LJ: NG-hydroxy-L-arginine and nitric oxide inhibit Caco-2 tumor cell proliferation by distinct mechanisms. Am J Physiol 1998, 275:R1256-R1264.
37. WAF1/CIP1 mediated by STAT1. Science 1996, 272:719-722.
38. Hobeika AC, Etienne W, Torres BA, Johnson HM, Subramaniam PS: IFN-g induction of p21WAF1 is required for cell cycle inhibition and suppression of apoptosis. J Interferon Cytokine Res 1999, 19:1351-1361.
39. WAF1/CIP1-Rb pathway and G1 arrest in human melanoma cells. Cancer Res 1999, 59:1278-1286.
40. Gooch JL, Herrera RE, Yee D: The role of p21 interferon-γ-mediated growth inhibition of human breast cancer cells. Cell Growth Differ 2000, 11:335-342.
41. Teerlink T, van Leeuwen PAM, Houdijk A: Plasma amino acids determined by liquid chromatography within 17 minutes. Clin Chem 1994, 40:245-249.
42. Satriano J, Ishizuka S, Archer DC, Blantz RC, Kelly CJ: Regulation of intracellular polyamine biosynthesis and transport by NO and cytokines TNF-α and IFN-γ. Am J Physiol 1999, 276:C892-C899.
43. Marquez J, Mates JM, Quesada AR, Medina MA, Nunez de Castro I, Sanchez-Jimenez F: Altered ornithine metabolism in tumor-bearing mice. Life Sci 1989, 45:1877-1884.
44. Wu G, Morris SM: Arginine metabolism: nitric oxide and beyond. Biochem J 1998, 336:1-17.
45. Kepka-Lenhart D, Mistry SK, Wu G, Morris SM: Arginase I: a limiting factor for nitric oxide and polyamine synthesis by activated macrophages? Am J Physiol 2000, 279:R2237-R2242.
46. Li H, Meininger CJ, Hawker JR, Haynes TE, Kepka-Lenhart D, Mistry SK, Morris SM, Wu G: Regulatory role of arginase I and II in nitric oxide, polyamine, and proline syntheses in endothelial cells. Am J Physiol 2001, 280:E75-E82.
47. Wei LH, Wu G, Morris SM, Ignarro LJ: Elevated arginase I expression in rat aortic smooth muscle cells increases cell proliferation. Proc Natl Acad Sci USA 2001, 98:9260-9264.
48. Louis CA, Mody V, Henry WL, Reichner JS, Albina JE: Regulation of arginase isoforms I and II by IL-4 in cultured murine peritoneal macrophages. Am J Physiol 1999, 276:R237-R242.
49. Schneider E, Dy M: The role of arginase in the immune response. Immunol Today 1985, 6:136-140.
50. Park KGM, Hayes PD, Garlick PJ, Sewell H, Eremin O: Stimulation of lymphocyte natural cytotoxicity by L-arginine. Lancet 1991, 337:645-646.
51. Wu CW, Chi CW, Ho CK, Chien SL, Liu WY, Peng FK, Wang SR: Effect of arginase on splenic killer cell activity in patients with gastric cancer. Digest Dis Sci 1994, 39:1107-1112.